Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes.

Taylor K, Kim D, Nielsen LL, Aisporna M, Baron AD, Fineman MS

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme1 Oct 2005Cited by 30 (Europe PMC)

PMID16278786DOI10.1055/s-2005-870529PepBankPUB-16278786

Publisher page PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanNon-randomized trialPharmacokinetics
In type 2 diabetes, plasma exenatide concentrations increased in proportion to infusion dose.
In plain wordsExenatide blood levels rose in proportion to dose in patients with type 2 diabetes.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseDose proportionality of plasma concentrations
Study
n = 12
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
0.2-0.8 microg/kg/day · continuous subcutaneous infusion · 23 hAs given in this study (human).
Source sentences
Summary
Plasma exenatide concentrations were dose-proportional.
3 context sentences(design, population, supporting numbers)
Summary · context
This study examined the effects of a continuous subcutaneous (SC) infusion of exenatide (0.2, 0.4, 0.6, or 0.8 microg/kg/day) or placebo (PBO) on glycemic control over 23 h intervals.
Summary · context
Twelve subjects with type 2 diabetes treated with metformin and/or diet received 10 infusions (4 exenatide, 6 PBO) on consecutive days.
Summary · context
Exenatide was given in a dose-increasing design with at least one placebo infusion between each exenatide infusion, and with meals and a snack provided during the first 14 h of infusion.
Report a problemFND-1627878601
02HumanNon-randomized trialEfficacy outcome
In type 2 diabetes, plasma glucose from 4 to 23 h of infusion was lower in all exenatide arms than with placebo.
In plain wordsBlood sugar was lower with every exenatide infusion dose than placebo in patients with type 2 diabetes.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePlasma glucose
Study
n = 12
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.2-0.8 microg/kg/day · continuous subcutaneous infusion · 23 hAs given in this study (human).
Source sentences
Summary
Plasma glucose (4-23 h) was lower in all exenatide arms compared to placebo (p<0.0001).
3 context sentences(design, population, supporting numbers)
Summary · context
This study examined the effects of a continuous subcutaneous (SC) infusion of exenatide (0.2, 0.4, 0.6, or 0.8 microg/kg/day) or placebo (PBO) on glycemic control over 23 h intervals.
Summary · context
Twelve subjects with type 2 diabetes treated with metformin and/or diet received 10 infusions (4 exenatide, 6 PBO) on consecutive days.
Summary · context
Exenatide was given in a dose-increasing design with at least one placebo infusion between each exenatide infusion, and with meals and a snack provided during the first 14 h of infusion.
Report a problemFND-1627878602
03HumanNon-randomized trialEfficacy outcome
In type 2 diabetes, the insulin/glucagon ratio increased from before to after infusion in combined exenatide arms but not placebo arms.
In plain wordsThe insulin-to-glucagon ratio rose with exenatide infusion but stayed unchanged with placebo in patients with type 2 diabetes.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseInsulin/glucagon ratio
Study
n = 12
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.2-0.8 microg/kg/day · continuous subcutaneous infusion · 23 hAs given in this study (human).
Source sentences
Summary
The change in insulin/glucagon ratio and amylin concentrations from pre-infusion to post-infusion was increased (p<0.005, p<0.05, respectively) in the combined exenatide arms, but remained unchanged in the placebo groups.
3 context sentences(design, population, supporting numbers)
Summary · context
This study examined the effects of a continuous subcutaneous (SC) infusion of exenatide (0.2, 0.4, 0.6, or 0.8 microg/kg/day) or placebo (PBO) on glycemic control over 23 h intervals.
Summary · context
Twelve subjects with type 2 diabetes treated with metformin and/or diet received 10 infusions (4 exenatide, 6 PBO) on consecutive days.
Summary · context
Exenatide was given in a dose-increasing design with at least one placebo infusion between each exenatide infusion, and with meals and a snack provided during the first 14 h of infusion.
Report a problemFND-1627878603
04HumanNon-randomized trialEfficacy outcome
In type 2 diabetes, amylin concentrations increased from before to after infusion in combined exenatide arms but not placebo arms.
In plain wordsAmylin levels rose with exenatide infusion but stayed unchanged with placebo in patients with type 2 diabetes.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseAmylin concentrations
Study
n = 12
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.2-0.8 microg/kg/day · continuous subcutaneous infusion · 23 hAs given in this study (human).
Source sentences
Summary
The change in insulin/glucagon ratio and amylin concentrations from pre-infusion to post-infusion was increased (p<0.005, p<0.05, respectively) in the combined exenatide arms, but remained unchanged in the placebo groups.
3 context sentences(design, population, supporting numbers)
Summary · context
This study examined the effects of a continuous subcutaneous (SC) infusion of exenatide (0.2, 0.4, 0.6, or 0.8 microg/kg/day) or placebo (PBO) on glycemic control over 23 h intervals.
Summary · context
Twelve subjects with type 2 diabetes treated with metformin and/or diet received 10 infusions (4 exenatide, 6 PBO) on consecutive days.
Summary · context
Exenatide was given in a dose-increasing design with at least one placebo infusion between each exenatide infusion, and with meals and a snack provided during the first 14 h of infusion.
Report a problemFND-1627878604
05HumanNon-randomized trialSafety outcome
In type 2 diabetes, nausea was among the most common treatment-emergent adverse events with exenatide infusion.
In plain wordsNausea was among the most common adverse events with exenatide infusion in patients with type 2 diabetes.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableNausea
Study
n = 12
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0.2-0.8 microg/kg/day · continuous subcutaneous infusion · 23 hAs given in this study (human).
Source sentences
Summary
Nausea and vomiting were the most common treatment emergent adverse events.
3 context sentences(design, population, supporting numbers)
Summary · context
This study examined the effects of a continuous subcutaneous (SC) infusion of exenatide (0.2, 0.4, 0.6, or 0.8 microg/kg/day) or placebo (PBO) on glycemic control over 23 h intervals.
Summary · context
Twelve subjects with type 2 diabetes treated with metformin and/or diet received 10 infusions (4 exenatide, 6 PBO) on consecutive days.
Summary · context
Exenatide was given in a dose-increasing design with at least one placebo infusion between each exenatide infusion, and with meals and a snack provided during the first 14 h of infusion.
Report a problemFND-1627878605
06HumanNon-randomized trialSafety outcome
In type 2 diabetes, vomiting was among the most common treatment-emergent adverse events with exenatide infusion.
In plain wordsVomiting was among the most common adverse events with exenatide infusion in patients with type 2 diabetes.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableVomiting
Study
n = 12
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0.2-0.8 microg/kg/day · continuous subcutaneous infusion · 23 hAs given in this study (human).
Source sentences
Summary
Nausea and vomiting were the most common treatment emergent adverse events.
3 context sentences(design, population, supporting numbers)
Summary · context
This study examined the effects of a continuous subcutaneous (SC) infusion of exenatide (0.2, 0.4, 0.6, or 0.8 microg/kg/day) or placebo (PBO) on glycemic control over 23 h intervals.
Summary · context
Twelve subjects with type 2 diabetes treated with metformin and/or diet received 10 infusions (4 exenatide, 6 PBO) on consecutive days.
Summary · context
Exenatide was given in a dose-increasing design with at least one placebo infusion between each exenatide infusion, and with meals and a snack provided during the first 14 h of infusion.
Report a problemFND-1627878606
07HumanNon-randomized trialEfficacy outcome
In type 2 diabetes, exenatide infusion appeared to benefit beta-cell function as assessed by proinsulin/insulin ratios.
In plain wordsIn patients with type 2 diabetes, exenatide infusion appeared to benefit insulin-producing cell function, assessed by proinsulin-to-insulin ratios.
Peptide
Exenatide (exendin-4)
Outcome
Direction not reportedBeta-cell function assessed by proinsulin/insulin ratios
Study
n = 12
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.2-0.8 microg/kg/day · continuous subcutaneous infusion · 23 hAs given in this study (human).
Source sentences
Summary
Exenatide infusion also appeared to have positive effects on beta-cell and alpha-cell function as measured by proinsulin/insulin ratios and mean glucagon concentrations.
3 context sentences(design, population, supporting numbers)
Summary · context
This study examined the effects of a continuous subcutaneous (SC) infusion of exenatide (0.2, 0.4, 0.6, or 0.8 microg/kg/day) or placebo (PBO) on glycemic control over 23 h intervals.
Summary · context
Twelve subjects with type 2 diabetes treated with metformin and/or diet received 10 infusions (4 exenatide, 6 PBO) on consecutive days.
Summary · context
Exenatide was given in a dose-increasing design with at least one placebo infusion between each exenatide infusion, and with meals and a snack provided during the first 14 h of infusion.
Report a problemFND-1627878607
08HumanNon-randomized trialEfficacy outcome
In type 2 diabetes, exenatide infusion appeared to benefit alpha-cell function as assessed by mean glucagon concentrations.
In plain wordsIn patients with type 2 diabetes, exenatide infusion appeared to benefit glucagon-producing cell function, assessed by average glucagon levels.
Peptide
Exenatide (exendin-4)
Outcome
Direction not reportedAlpha-cell function assessed by mean glucagon concentrations
Study
n = 12
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.2-0.8 microg/kg/day · continuous subcutaneous infusion · 23 hAs given in this study (human).
Source sentences
Summary
Exenatide infusion also appeared to have positive effects on beta-cell and alpha-cell function as measured by proinsulin/insulin ratios and mean glucagon concentrations.
3 context sentences(design, population, supporting numbers)
Summary · context
This study examined the effects of a continuous subcutaneous (SC) infusion of exenatide (0.2, 0.4, 0.6, or 0.8 microg/kg/day) or placebo (PBO) on glycemic control over 23 h intervals.
Summary · context
Twelve subjects with type 2 diabetes treated with metformin and/or diet received 10 infusions (4 exenatide, 6 PBO) on consecutive days.
Summary · context
Exenatide was given in a dose-increasing design with at least one placebo infusion between each exenatide infusion, and with meals and a snack provided during the first 14 h of infusion.
Report a problemFND-1627878608

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.